Product Information
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.1881 per EA under NDC 62332005230. Its NADAC has been published 526 times since Sep 7, 2016.
FDA first approved this application on Oct 15, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5; 300 mg/1; mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332005230
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA091370FDA Approved
10/15/2012
TE Code
AB
On Market Since
5/23/2016
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has been published 526 times since Sep 7, 2016, and over the history we have for it it has declined 51.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1881 per EA |
|---|---|
| All-time high | $0.3889 (Mar 15, 2017) |
| All-time low | $0.1656 (May 22, 2024) |
| 52-week high | $0.2129 |
| 52-week low | $0.1881 |
| Median price | $0.2612 |
| Average price | $0.2637 |
| Largest weekly change | +34.4% (Jun 19, 2024) |
| Weeks tracked | 526 |
| Tracking since | Sep 7, 2016 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 10% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Irbesartan and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, manufactured by Alembic Pharmaceuticals Inc., is $0.1881 per EA (NDC 62332005230), effective Sep 30, 2026.
How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has declined 51.0%. It has been tracked across 526 weekly CMS publications since Sep 7, 2016.
What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
Since Sep 7, 2016, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has ranged from a low of $0.1656 (May 22, 2024) to a high of $0.3889 (Mar 15, 2017), with a median of $0.2612 per EA.
Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, is $0.1698 per EA — about 10% below IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB.
Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB (NDC 62332005230) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.